Eph receptor tyrosine kinases and their ligands (ephrins) have a pivotal role in the homeostasis of many adult organs and are widely expressed in the kidney. Glomerular diseases beginning with mesangiolysis can recover, with podocytes having a critical role in this healing process. We studied here the role of Eph signaling in glomerular disease recovery following mesangiolytic Thy1.1 nephritis in rats. EphB4 and ephrinBs were expressed in healthy glomerular podocytes and were upregulated during Thy1.1 nephritis, with EphB4 strongly phosphorylated around day 9. Treatment with NPV-BHG712, an inhibitor of EphB4 phosphorylation, did not cause glomerular changes in control animals. Nephritic animals treated with vehicle did not have morphological evidence of podocyte injury or loss; however, application of this inhibitor to nephritic rats induced glomerular microaneurysms, podocyte damage, and loss. Prolonged NPV-BHG712 treatment resulted in increased albuminuria and dysregulated mesangial recovery. Additionally, NPV-BHG712 inhibited capillary repair by intussusceptive angiogenesis (an alternative to sprouting angiogenesis), indicating a previously unrecognized role of podocytes in regulating intussusceptive vessel splitting. Thus, our results identify EphB4 signaling as a pathway allowing podocytes to survive transient capillary collapse during glomerular disease.
Thy1.1 nephritis is one of the most commonly used models to study the course of immunoglobulin A and other mesangioproliferative nephropathies. 1 To date, most of the studies have focused on mesangial and, to a lesser extent, endothelial cell recovery following capillary damage, 2 whereas data concerning the podocyte response are still scarce. Podocytes are terminally differentiated epithelial cells with a distinctive morphology. Their foot processes and the slit membrane are localized at the basolateral site, while a well-developed cell body faces the urinary space. 3 Proteins located at the basolateral site have been extensively studied owing to their involvement in maintaining podocyte attachment to the basement membrane and barrier function against proteinuria. 4, 5 It is, however, not unusual for apically expressed proteins to regulate the function of foot processes and overall podocyte homeostasis. 6, 7 Therefore, alterations in apical membrane domains are one of the events leading to podocyte degeneration. 8 Unlike endothelial and mesangial cells, podocytes have very limited capability of self-renewal, making their injury a critical step in the pathogenesis of nephropathies. 9 Recently ephrinB1, a ligand of the EphB family of receptor tyrosine kinases, has emerged as yet another protein located at the glomerular slit membrane. 10 The specific feature of these versatile molecules is the possibility of bidirectional signaling, where not only the Eph receptor (forward signaling) but also the membrane-bound ephrin ligand (reverse signaling) can convey an intracellular signal. Eph/ephrins have previously attracted a lot of attention owing to their crucial involvement in the development of the vascular and nervous systems. 11 Among Eph/ephrins, EphB4 and its ligand ephrinB2 were first described as critical molecules regulating vascular development, where EphB4-expressing venous endothelial cells assemble with ephrinB2-expressing arterial endothelium to form functional vasculature. As the EphB4/ephrinB2 pair acts in this setting as reciprocal signaling partners, their loss causes similar phenotypes in mouse embryos. 12 Also, there is evidence that EphB4/ephrinB2 control bone homeostasis 13 as well as vascular biology in the adult organism.
14 Eph/ephrins are also expressed in the adult kidney; 15, 16 however, their involvement in glomerular recovery from acute glomerulonephritis has not been addressed. Western blotting of glomeruli lysates showed that ephrinBs and EphB4 were upregulated during nephritis (n ¼ 4 in control (ctrl), n ¼ 5 at day (D) 21 and n ¼ 6 at D5, D9, and D14; each n is a glomerular lysate from one animal). (c) Phosphorylated ephrinBs (pEphrinBs) were detected in the glomeruli at D9 of nephritis, but not in the healthy rats. (d) EphB4 activation was detected at D9 of nephritis. (e-g) EphrinBs colocalized with podocin, a marker of podocyte foot processes, in healthy and nephritic glomeruli. (h-j) EphB4 staining was shifted towards the urinary space when compared to podocin fluorescence (enlarged area and arrows). (k) EphB4 mRNA was detected at the periphery of glomerular lobules at D9 of nephritis (arrows). n ¼ 4 in d, n ¼ 3 in k; d and k show representative images. IP, immunoprecipitation; PTyr, phosphotyrosine; WB, western blotting. *Po0.05; **Po0.01; ***Po0.001.
RESULTS

EphB4 receptor is markedly activated in the glomeruli of nephritic rats
Immunohistochemical analysis demonstrated protein expression of EphB4 receptor and ephrinBs in healthy rat glomeruli (Figure 1a ). Using the same antibodies, we did not detect EphB4 in mouse glomeruli (Supplementary Figure S1 online), in accordance with Takahashi et al. 17 and suggesting differences within rodents.
Western blot analysis of glomerular lysates showed a marked ephrinB upregulation and a milder increase of EphB4 during nephritis (Figure 1b) . Phosphorylated ephrinBs could not be detected in healthy glomeruli, but were readily observed upon nephritis induction (Figure 1c) . The most striking result, however, was a strong phosphorylation of EphB4 at day 9 of nephritis ( Figure 1d ). EphB4/ephrinBs could be also detected in the tubular epithelium (Supplementary Figures 1c-f and 2a-d online, respectively).
Colocalization studies detected ephrinBs along with the podocyte marker podocin in healthy and nephritic glomeruli (Figure 1e-g ). EphB4 showed, however, only weak or no colocalization with podocin (Figure 1h-j) . The receptor staining was strongest towards the urinary space (enlarged area and arrows). As podocin is a marker of foot processes, the EphB4 staining pattern is consistent with a predominant expression at the apical part of podocytes. No colocalization was observed between EphB4 and endothelial (CD31) or mesangial (a smooth muscle actin (aSMA)) markers (Supplementary Figure S2e-f online) .
To confirm podocyte-specific EphB4 expression during the disease, we performed in situ hybridization to detect EphB4 mRNA. Although the signal was not very strong, we could detect EphB4 mRNA at the outer rim of nephritic glomeruli, consistent with the localization within podocytes (Figure 1k , arrows).
NPV-BHG712 impairs glomerular recovery from Thy1.1 nephritis
To delineate the role of podocyte EphB4 during nephritis, we used NPV-BHG712, a novel and to date the only specific, in vivo-validated small-molecular-weight inhibitor of EphB4 phosphorylation. 18 Pharmacological data of NPV-BHG712 in rats are shown in Supplementary Figure S3 online.
In preliminary titration experiments, we showed that 50 mg/kg b.w. NPV-BHG712 delivered i.p. completely inhibited EphB4 phosphorylation (Figure 2a and b) . We then sought to exclude the potential off-target actions of NPV-BHG712. As NPV-BHG712 also inhibits EphB2 and EphA2, we looked for their glomerular expression. EphB2 was absent in rat glomeruli, whereas EphA2 was expressed but unphosphorylated in both healthy and nephritic glomeruli (Figure 2d and e) . Also, we showed that NPV-BHG712 had no effect on phosphorylated c-Src or extracellular signal-regulated kinases in nephritic rats, in sharp contrast to the complete inhibition of glomerular EphB4 activation (Figure 2c ). These results suggest that the observed biological end points are primarily due to inhibition of podocyte EphB4 signaling.
We next applied NPV-BHG712 to healthy rats according to the schedule depicted in Figure 3a . We did not observe any effects of NPV-BHG712 on podocyte number (Figure 3b ) and the glomerular morphology (Figure 3c-i) . NPV-BHG712 did not cause albuminuria, glomerulosclerosis, or microaneurysms (data not shown).
We then induced nephritis by a single i.v. shot of OX7 antibody, and randomly allocated animals to either NPV-BHG712 or the vehicle group. We chose to apply these compounds between day 5 and day 9 of glomerulonephritis ( Figure 4a ) because glomerular EphB4 phosphorylation was initiated during this critical time period. Kidney/body weight ratio and albuminuria were not influenced by NPV-BHG712 (Figure 4b and c) , but NPV-BHG712 aggravated the injury to glomerular capillaries as assessed by the presence of glomeruli with microaneurysms ( Figure 4d ) and further increased glomerular volume (Figure 4e ). Interestingly, EphB4 inhibition reduced the number of glomerular macrophages ( Figure 4f ), although overall macrophage number per section was still low compared to the total glomerular cellularity.
To gain a more global view of the molecular mechanisms of glomerular repair, we next focussed on other growth factors known to have an important role in glomeruli. We examined whether NPV-BHG712 treatment influences the expression of Tie-2 receptor relevant for capillary recovery from Thy1.1 nephritis, 19 platelet-derived growth factor receptor b important for mesangial normalization during nephritis, 20 and podocyte vascular endothelial growth factor (VEGF) maintaining VEGFR2-expressing endothelium. 21 Tie-2 receptor expression increased during nephritis and these changes were not influenced by EphB4 inhibition.
Platelet-derived growth factor receptor b was also upregulated in nephritic rats; this increase was even more pronounced following NPV-BHG712 treatment (Figure 4g ). VEGF was expressed by podocytes located at the glomerular periphery in nephritic animals; after NPV-BHG712 treatment, only single podocytes expressed this growth factor (Figure 4h , arrow).
Inhibition of EphB4 signaling during nephritis leads to podocyte injury Next, we evaluated podocyte morphology with different microscopy techniques. Podocytes of vehicle-treated nephritic rats were conspicuous cells with well-developed cell bodies (Figure 5a, d, and g) ; podocytes of NPV-BHG712-treated Prolonged NPV-BHG712 administration to nephritic rats increases albuminuria and impairs mesangial recovery
As we did not see any effect of EphB4 inhibition on albuminuria despite significant morphological changes, NPV-BHG712 or vehicle was administered to nephritic rats for a longer period of time (between days 5 and 21, Figure 6a ). We still observed a podocyte loss of about 20%, but now albuminuria increased significantly in NPV-BHG712-treated animals ( Figure 6b Figure 6m ). To address a potential toxicity of NPV-BHG712, weight change was monitored daily and the liver weight was recorded at the end of the experiment. After 21 days vehicle-treated nephritic rats were 130.5 ± 21.9 g heavier and the liver was 4.2 ± 0.1% of the total body weight at the end of the experiment (n ¼ 4). At the same time, NPV-BHG712-treated nephritic rats gained 125.5 ± 17.7 g and their liver was 4.2 ± 0.3% of the body weight (n ¼ 4). Thus, there were no differences with regard to these parameters between compound-and vehicle-treated rats.
NPV-BHG712 application to Thy1.1 nephritic rats inhibits intussusceptive angiogenic repair
As we and others have shown that intussusceptive angiogenesis is required for glomerular capillary recovery from Thy1.1 nephritis, 22, 23 we examined the dynamics of this process after NPV-BHG712 administration to nephritic rats. In contrast to sprouting angiogenesis, intussusception causes capillary growth by insertion of tissue pillars inside the vessel lumen. This process corresponds to 'tiny holes' on scanning electron microscope images, 24 which were absent in glomerular casts of healthy rats (Figure 7a and d) . Capillaries of nephritic vehicle-treated rats presented multiple openings (Figure 7b ) that could be divided into tiny holes and small capillary loops based on their size (Figure 7e , arrows and arrowheads, respectively). In contrast, tiny holes and small capillary loops were only occasionally seen in NPV-BHG712-treated nephritic animals (Figure 7c and f, arrows and arrowheads). Additionally, the capillary channels in this group appeared to be heterogeneous and less dense in some lobules (Figure 7c and f) . Morphometrical analysis revealed that NPV-BHG712 administration to nephritic rats reduced the density of pillars and small capillary loops as compared to vehicle-treated animals (Figure 7g and h) . Glomerular endothelial cells, a cell type critical for pillar formation, 24 were seen throughout the entire glomerular surface in healthy rats, whereas at day 9 CD31-positive cells were positioned at the periphery of glomerular lobules. In the NPV-BHG712-treated nephritic group, glomerular capillaries were less dense, i.e., CD31 immunoreactivity was often absent at the periphery of the lobules (Figure 7i , arrows) and the area occupied by CD31-positive capillary loops was significantly diminished (Figure 7j ).
EphB4 forward signaling partially reverses transforming growth factor (TGF)b1-induced podocyte apoptosis in vitro
In view of these findings we hypothesized that podocyte EphB4 forward signaling could rescue podocytes from other types of injury, and performed in vitro studies with a wellcharacterized, immortalized podocyte cell line. 25 Differentiated and undifferentiated podocytes express EphB4 receptor and ephrinBs (Figure 8a ). EphB4 was not phosphorylated in differentiated podocytes, but was activated by exogenous ephrinB2/Fc (Figure 8b ). EphB4 and ephrinB2 colocalized at the plasma membrane, but EphB4 was also located in cytoplasmic clusters (Figure 8c ). Phosphorylated ephrinBs were expressed at the plasma membrane (Figure 8d , arrow) and additionally colocalized with phalloidin at the end of stress fibers consistent with expression in focal adhesions (Figure 6d , magnified picture). As we had found increased podocyte apoptosis in nephritic rats treated with NPV-BHG712 ( Figure  5p and q), we looked for an in vitro correlate of this effect. Serum starvation induced the presence of the apoptosis marker poly (ADP-ribose) polymerase fragment 26 and this effect was potentiated by TGFb1, 27 a cytokine reported to be released during Thy1.1 nephritis by activated mesangial cells. 28 Coincubation of TGFb1 with ephrinB2/Fc reduced the abundance of the poly (ADP-ribose) polymerase fragment. However, the addition of NPV-BHG712 blocked the protective effects of ephrinB2/Fc on TGFb1-mediated apoptosis (Figure 8e ).
DISCUSSION
EphB4 activation in podocytes during Thy1.1 nephritis is a protective mechanism against injury During Thy1.1 nephritis, podocytes, in contrast to mesangium and endothelium, do not present much morphological evidence of injury. However, it has already been suggested that podocytes help to preserve the glomerular architecture until proliferation and regeneration of the mesangial cells. 29 Podocytes thus seem to have a key role during the early phase of injury; however, little is known about the mechanisms allowing them to react to the transient capillary collapse. We present evidence that activation of EphB4 forward signaling is one of these mechanisms.
In our model, podocyte injury and loss was not accompanied by aggravation of the albuminuria when rats were treated with the compound for a short period of time. However, NPV-BHG712 administration over 16 days significantly increased albuminuria while the podocyte loss remained stable at about 20%. At this time point (day 21 of nephritis) the remaining podocytes displayed a normal morphology but the mesangial reaction was clearly disturbed, with large hypocellular areas accompanied by matrix expansion. In our model, thus, the matrix production and cell activation does not correspond to the overall mesangial cellularity. One explanation would be that the aSMA-positive area is increased together with the decrease in cell number due to the mesangial hypertrophy. The mesangial phenotype we observed is quite reminiscent of the mesangial cell growth during the diabetic state where a transient phase of mesangial proliferation is followed by growth arrest, hypertrophy, and an increase in synthesis of the extracellular matrix. 30 Interestingly, it has also been shown that mesangial proliferation can be dissociated from mesangial cell migration. 31 These findings strongly suggest that an intact podocyte EphB4 signaling is required for mesangial normalization after acute Thy1.1 nephritis. The increased number of microaneurysms at day 9 of nephritis could also be explained by the observed reduced mesangial cellularity consistent with mesangiolysis.
Within the glomerulus, the importance of paracrine signaling has already been well established between podocytes secreting VEGF and the VEGFR2-expressing endothelium. 21 Interestingly, a case report of a patient treated with anti-VEGF antibody in combination with interferon a2b showed a strikingly similar glomerular phenotype to our rats: mesangial interposition, subendothelial electron-lucent deposits, mesangial hypocellularity, but relatively intact foot processes and mild proteinuria. 32 Furthermore, Das et al. 33 reported recently that in hepatic stellate cells VEGF production is controlled by EphB4. Our results suggest that a similar mechanism operates in nephritic podocytes.
What triggers podocyte EphB4 signaling during Thy1.1 nephritis?
Our findings raise an important issue as to which stimuli could trigger EphB4 signaling during acute Thy1.1 nephritis. One explanation would be that EphB4 receptor signals in response to mechanical stress caused by podocyte stretching due to the capillary enlargement, as it has been shown that podocytes respond to this kind of challenge. 34, 35 In the NPV-BHG712-treated nephritic group, glomerular volume was increased together with a reduced podocyte number; during that period, however, we could never observe denuded basement membranes. It is therefore conceivable that podocytes are stretched to take over the function of lost cells. Furthermore, the endothelial expression of Eph receptors and ephrins is regulated by altered shear stress. 36, 37 A second question addresses the role of ephrinBs in activating the receptor. EphB4 and ephrinBs are expressed at different podocyte membrane compartments, so how they could interact directly? One possibility would be that EphB4 expressed at the apical part would come into contact with ephrinBs located at the foot processes of detached podocytes 'swimming' in the urinary space. Another potential mechanism to explore would be a cross-talk between EphB4 and other RTKs as Eph receptors are quite promiscuous molecules in other cell systems. [38] [39] [40] [41] [42] The extensive dissection of signaling cross-talks between EphB4 and other RTKs in podocytes are beyond the scope of this work and will be the topic of another project. 
EphB4 activation regulates intussusceptive angiogenesis during capillary repair
Intussusceptive angiogenesis, an alternative to the sprouting mode of angiogenesis, is a major mechanism permitting the expansion of the primary capillary plexus and angioadaptation. 43 We and others have identified intussusception as the main angiogenic mode leading to restitution of the glomerular capillary structure and filtration surface in Thy1.1 nephritis. 22, 23 Intussusception starts when endothelial cells invade the vessel lumen and form a transluminal pillar, which is further stabilized by mesangial cells. 44 Podocytes are regarded as pericyte-like cells of glomerular capillaries; 45, 46 therefore they could contribute to pillar formation and/or stabilization. As (i) EphB4 is expressed only in glomerular podocytes and (ii) EphB4 blocking leads to downregulation of the intussusceptive response, a previously unrecognized role of podocytes in regulating intussusceptive angiogenesis is conceivable. A possible scenario is that EphB4 signaling enables the foot processes to exert mechanical forces on endothelial cells via rearrangement of the cytoskeleton. EphB4 could also regulate the secretion of molecules influencing the pillarforming endothelium. Indeed, preliminary results from our laboratory suggest that podocytes secrete VEGF in response to EphB4 activation by its cognate ligand ephrinB2/Fc. However, EphB4 is not the sole regulator of glomerular intussusception as pillars already form at day 5 of nephritis, 23 a time point at which EphB4 is not yet phosphorylated.
In aggregate, our results demonstrate that EphB4 signaling initiated during Thy1.1 nephritis is an important mechanism allowing podocytes to adapt to a potentially deleterious event and thus survive. Given the very limited possibility of podocyte repopulation, our findings are important to identify pathways maintaining their homeostasis upon injury and, in a broader sense, shed further light on the versatile roles of the Eph/ephrin system in the adult organism.
MATERIALS AND METHODS Primary antibodies
The detailed list of primary antibodies is shown in Supplementary  Figure S4 online. Anti-podocin antibody was a kind gift from Prof. P Mundel (Department of Medicine, University of Miami, Miami, FL).
Animal experimentation
All procedures were conducted according to the NIH guidelines for the care and use of laboratory animals and with the approval of the local Animal Ethics Committee. Male Wistar rats (170-190 g) were obtained from Charles River Laboratories, Sulzfeld, Germany. Acute Thy1.1 glomerulonephritis was induced by a single intravenous injection of 1 mg/kg b.w. of monoclonal OX7 antibody. 47 Rats were killed on days 5, 9, 14, and 21. Animals receiving the same volume of saline served as controls. NPV-BHG712 experiments: the compound was administered daily (time indicated on each graph in Figures 3,  4, and 6 ), i.p., at the dose of 50 mg/kg b.w. Control animals received the same volume of vehicle (PEG300).
Urinalysis
The high-performance liquid chromatography technique with silicabased standard size exclusion column (Waters, Milford, MA) was used to quantify the urinary albumin excretion in urine specimens collected for 24 h.
Glomeruli isolation, western blotting and immunoprecipitation Glomeruli were then isolated using the standard sieving method and homogenized in lysis buffer. 23 Isolated proteins were incubated with the precipitating antibody overnight at 4 1C, then with Protein A/G Plus-Agarose beads for 2 h at 4 1C. Pulled proteins were resolved on SDS-PAGE. When indicated, membranes were stripped with 0.1 mol/l glycine pH 2.5 and reprobed with the appropriate antibody to confirm the efficiency of immunoprecipitation, or with b-actin to confirm equal lane loading.
Light and electron microscopy; staining protocols Semithin sections, tissues dried at critical point, and transmission electron micrograph sections were prepared as previously described. 23 The classical ABC method on formalin-fixed paraffin-embedded tissue was employed to detect proteins with immunohistochemistry. Colocalization studies were performed by indirect immunofluorescence staining on cryosections and evaluated with laser scanning microscopy (LSM510; Carl Zeiss, Heidelberg, Germany). TUNEL staining was performed with the In Situ Cell Death Detection Kit according to the manufacturer's instructions (Roche Diagnostics, Basel, Switzerland). TUNEL þ podocytes and mesangial cells were recognized based on their glomerular location and morphology.
In situ hybridization
In situ hybridization for EphB4 mRNA was performed on formalinfixed frozen sections with the probe validated in Erber et al.
14 The probe was labelled with digoxygenin (in situ RNA labelling kit; Roche Diagnostics) recognized by anti-digoxygenin antibody coupled with alkaline phosphatise (Roche Diagnostics). The reaction was developed with BM Purple AP substrate, precipitating (Roche Diagnostics).
Vascular casting and intussusception quantification
Vascular casts and intussusception quantification were performed as previously described. 23 Tiny hole/small capillary loop appearance was expressed as numerical density per vessel area.
The vessel area was estimated with iTEM software (Olympus, Hamburg, Germany) using the grid method: a grid was placed on each photograph included in the quantification and the number of grid intersections hitting a capillary was quantified. As numerical density per vessel area is the ratio between the number of tiny holes/ small capillary loops and the relative vessel area, it has no unit.
Morphometry
Glomeruli volume, V G , was quantified from scanning electron microscope pictures of vascular casts as described previously. 23 Macrophages were recognized on formalin-fixed paraffin-embedded kidney section as ED1-positive cells, and counting of glomeruli with microaneurysms was performed on formalin-fixed paraffin-embedded kidney section stained with hematoxylin and eosin. Quantification of podocyte number per glomerulus was performed as described previously, 48 but podocytes were recognized on formalin-fixed paraffin-embedded kidney section as synaptopodin-expressing cells and only podocytes with nucleus (hematoxylin) on the cross section were counted.
aSMA-and fibronectin-positive area per glomerulus and glomerulosclerosis were quantified with ImageJ software (NIH, Bethesda, MA), the relative glomerulosclerosis area was obtained by dividing the sclerotic area by the area of the whole glomerular tuft (no units). The VEGF downregulation following NPV-BHG712 administration was quantified by counting the VEGF-expressing podocytes and dividing this number by the podocyte total count in the glomerulus. The relative CD31-positive area per glomerular section was quantified with the grid method (ImageJ software). The grid was placed on each glomerular picture stained with CD31 (original magnification Â 600) and the number of grid intersections hitting a capillary loop was counted.
At least 30 glomeruli were examined for each morphometrical analysis.
Statistical analysis
All data are expressed as mean±s.d. Statistical analysis was performed with GraphPad Prism Software (GraphPad Software, La Jolla, CA). One-way ANOVA with Bonferroni post-hoc test was used to compare selected pairs of columns. When a scattered plot type of graph is shown, each point represents one animal. When a column bar graph is used, the number of animals is specified in the legends.
Cell culture and in vitro experiments
An immortalized mouse podocyte cell line was obtained from Dr Andreas Jehle (Department of Biomedicine, University Hospital Basel, Basel, Switzerland) and cultivated as described previously. 25 For immunostaining, cells were fixed with 2% PFA, 4% sucrose in PBS, and permeabilized with 0.3% Triton-X. Fluorochromeconjugated phalloidin was obtained from Invitrogen (Karlsruhe, Germany).
Podocytes were incubated with TGFb1 (Invitrogen; 10 nmol/l) and ephrinB2/Fc (1 mg/ml; R&D Systems) in serum-free media. When indicated, cells were incubated with 50 nmol/l BHG712 diluted in DMSO. After 48 h, cells were collected in lysis buffer and proteins were isolated for western blotting. DISCLOSURE GMB, PH, and PIW are employed by Novartis. The remaining authors declared no competing interests. Figure S1 . Immunohistochemical detection of EphB4 protein on rat and mouse kidney sections. Figure S2 . Pattern of ephrinBs expression in the rat kidney and EphB4 colocalization study in nephritic glomeruli. Figure S3 . Pharmacokinetic profile of NVP-BHG712 in conscious rats after (a) intravenous and (b) oral administration. Figure S4 . 
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